S

Syndax Pharmaceuticals

D
SNDX
USD
0.61
(3.387%)
Market Closed
43,298.00
Volume
-3.94
EPS
-
Div Yield
-5.476471
P/E
1,584,494,185.96
Market Cap
Today
3.3870%
1 Week
3.387%
1 Month
-9.126%
6 Months
-16.088%
12 Months
9.080%
Year To Date
-13.796%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
J
JAZZ
1.66
(1.5152%)
USD
I
INCY
1.67
(2.5625%)
USD
B
BLUE
-0.0046
(-0.9287%)
USD
X
XNCR
0.36
(1.7266%)
USD
G
GERN
0.22
(4.878%)
USD
A
ADAP
-0.02
(-1.9417%)
USD
M
MRTX
(%)
USD

Title:
Syndax Pharmaceuticals

Sector:
Healthcare
Industry:
Biotechnology
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.
Do you need help or have a question?
Contact Us